Cover Image

Update breast cancer 2019 part 1 - Implementation of study results of novel study designs in clinical practice in patients with early breast cancer = Update Mammakarzinom 2019 Teil 1 - Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result,...

Full description

Saved in:
Bibliographic Details
Main Authors: Hartkopf, Andreas (Author) , Schütz, Florian (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 12. März 2019
In: Geburtshilfe und Frauenheilkunde
Year: 2019, Volume: 79, Issue: 03, Pages: 256-267
ISSN:1438-8804
DOI:10.1055/a-0842-6614
Online Access:Verlag, Volltext: https://doi.org/10.1055/a-0842-6614
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0842-6614
Get full text
Author Notes:Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Naiba Nabieva, Florin-Andrei Taran, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Tanja N. Fehm, Hans-Christian Kolberg, Friedrich Overkamp, Andreas Schneeweiss, Hans Tesch
Description
Summary:For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.
Item Description:Gesehen am 19.07.2019
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-0842-6614

Similar Items